MediciNova’s MN-166 shows efficacy in lung injury study

MediciNova collaborator Perenlei Enkhbaatar, Professor, Department of Anesthesiology, University of Texas Medical Branch, presented new data and results of a nonclinical study evaluating MN-166 – ibudilast – in a chlorine gas-induced acute lung injury – CIALI – model at the Society of Toxicology 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah. The primary objective of this nonclinical efficacy study was to determine the safety and pharmacological activity of MN-166 following ALI induced by chlorine gas inhalation in a clinically relevant translational ovine model. The primary endpoint was the mean change in the pulmonary function measure PaO2/FiO2. Additional endpoints included survival, lung mechanics, lung injury, and edema formation. MN-166 20 mg and rolipram treatment resulted in greater improvement in mean PaO2/FiO2 and peak airway pressure but dissipated after Hour 12. MN-166 20 mg showed greater improvement in mean PaO2/FiO2 ratio. MN-166 20 mg also showed greater improvement in peak airway pressure, plateau airway pressure, pulmonary artery pressure, and lung injury score vs. other treatment groups. MN-166 20 mg also maintained cardiac and kidney function compared to the other treatment groups. MN-166 20 mg treatment demonstrated a greater survival benefit than the other treatment groups. All animals in the MN-166 20 mg group survived the 48-hour monitoring period, while 25% animals were euthanized early in other groups upon reaching the euthanasia criteria.